These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 10431138)

  • 1. Prevention strategies for respiratory syncytial virus: passive and active immunization.
    Englund JA
    J Pediatr; 1999 Aug; 135(2 Pt 2):38-44. PubMed ID: 10431138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of respiratory syncytial virus vaccine development.
    Polack FP; Karron RA
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP; Weisman LE
    Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge.
    Fisher RG; Johnson JE; Dillon SB; Parker RA; Graham BS
    J Infect Dis; 1999 Sep; 180(3):708-13. PubMed ID: 10438358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
    J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human and bovine respiratory syncytial virus vaccine research and development.
    Meyer G; Deplanche M; Schelcher F
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):191-225. PubMed ID: 17720245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
    Cardenas S; Auais A; Piedimonte G
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of bronchiolitis.
    Pringle CR
    Paediatr Respir Rev; 2000 Sep; 1(3):228-34. PubMed ID: 12531084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants.
    Lanari M; Silvestri M; Rossi GA
    Curr Drug Metab; 2013 Feb; 14(2):216-25. PubMed ID: 22935064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.
    Englund JA
    Pediatr Infect Dis J; 1994 May; 13(5):449-53. PubMed ID: 8072835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.